Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib in CLL/SLL Post-BTKi
NCT03370185Phase 2Withdrawn
- Sponsor
- Secura Bio
- Start
- Feb 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Secura Bio. Planned start Feb 2018; status: withdrawn.
02
Drugs
duvelisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03370185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370185.